Tumor Factors | Overall (n = 395) | Caucasian (n = 307) | African American (n = 39) | Hispanic (n = 10) | Asian-Pacific Islander (n = 24) | Unknown/ Others (n = 15) | p value* |
Histopathology |
|
|
|
|
|
| 0.419 |
DCIS | 307 (77.7%) | 242 (78.8%) | 29 (74.4%) | 7 (70.0%) | 19 (79.2%) | 10 (66.7%) |
|
DCIS with IDC | 70 (17.7%) | 52 (16.9%) | 6 (15.4%) | 2 (20.0%) | 5 (20.8%) | 5 (33.3%) |
|
DCIS with LCIS | 18 (4.6%) | 13 (4.2%) | 4 (10.3%) | 1 (10.0%) | 0 (0.0%) | 0 (0.0%) |
|
Tumor characteristics |
|
|
|
|
|
|
|
Median tumor size (cm) | 1.0 | 1.0 | 0.2 | 0.1 | 0.1 | 0.1 | 0.861 |
Multicentricity | 47 (11.9%) | 34 (11.1%) | 5 (12.8%) | 2 (20.0%) | 3 (12.5%) | 3 (20.0%) | 0.772 |
Multifocality | 92 (23.3%) | 72 (23.5%) | 9 (23.1%) | 3 (30.0%) | 3 (12.5%) | 5 (33.3%) | 0.615 |
High Grade | 140 (35.4%) | 107 (34.9%) | 16 (41.0%) | 3 (30.0%) | 10 (41.7%) | 4 (26.7%) | 0.931 |
Comedonecrosis | 264 (66.8%) | 199 (64.8%) | 29 (74.4%) | 7 (70.0%) | 19 (79.2%) | 10 (66.7%) | 0.364 |
Receptor status |
|
|
|
|
|
|
|
ER positive | 235 (59.5%) | 182 (81.3%) | 21 (77.8%) | 9 (90.0%) | 12 (70.6%) | 11 (84.6%) | 0.737 |
PR positive | 182 (46.1%) | 139 (62.1%) | 17 (63.0%) | 7 (70.0%) | 9 (52.9%) | 10 (79.6%) | 0.721 |
HER-2/neu positive | 24 (6.1%) | 21 (50.0%) | 2 (50.0%) | 0 (0.0%) | 0 (0.0%) | 1 (25.0%) | 0.469 |
USC/Van Nuys prognostic index |
|
|
|
|
|
| <0.001 |
Low score | 130 (32.9%) | 103 (33.6%) | 15 (38.5%) | 0 (0.0%) | 5 (20.8%) | 7 (46.7%) |
|
Intermediate score | 264 (66.8%) | 204 (66.4%) | 24 (61.5%) | 10 (100%) | 19 (79.2%) | 7 (46.7%) |
|
High score | 1 (0.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (6.7%) |
|